Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary (8) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Withdrawn applications Remove Withdrawn applications filter Paediatric investigation plans Remove Paediatric investigation plans filter Referrals Remove Referrals filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Summaries of opinion (21) Apply Summaries of opinion filter Orphan designations (136) Apply Orphan designations filter

Product number

Patient safety

Yes (10) Apply Yes filter

Authorisation status

Authorised (413) Apply Authorised filter Refused (3) Apply Refused filter Withdrawn (60) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Withdrawal type

Initial authorisation (6) Apply Initial authorisation filter Post-authorisation (9) Apply Post-authorisation filter

Withdrawal date

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (18) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (175) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (2) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (38) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (27) Apply Yes filter

Compliance procedure number

Referral name

Referral status

European Commission final decision (15) Apply European Commission final decision filter Opinion provided by Committee for Medicinal Products for Human Use (1) Apply Opinion provided by Committee for Medicinal Products for Human Use filter

Referral safety status

Yes (7) Apply Yes filter

Referral type

Article 20 procedures (12) Apply Article 20 procedures filter Article 31 referrals (4) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CAT-CHMP-EC (1) Apply PRAC-CAT-CHMP-EC filter PRAC-CHMP-EC (12) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (4) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (12) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (10) Apply Risk minimisation measures filter Suspension (2) Apply Suspension filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Medicine type

Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Biosimilar Remove Biosimilar filter Conditional approval Remove Conditional approval filter Exceptional circumstances Remove Exceptional circumstances filter Generic (323) Apply Generic filter Orphan medicine (320) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

778 results

Remove all filtersRemove all filters

Categories Human Remove Human filter

Medicine type Accelerated assessment Remove Accelerated assessment filter Conditional approval Remove Conditional approval filter Additional monitoring Remove Additional monitoring filter Exceptional circumstances Remove Exceptional circumstances filter Biosimilar Remove Biosimilar filter

Medicine Paediatric investigation plans Remove Paediatric investigation plans filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Withdrawn applications Remove Withdrawn applications filter Referrals Remove Referrals filter

Sort by

List item

Human medicine European public assessment report (EPAR): Xenpozyme (updated)

Olipudase alfa, Acid sphingomyelinase deficiency (ASMD) type A/B or type B
Date of authorisation: 24/06/2022, , , Revision: 1, Authorised, Last updated: 03/05/2023
List item

Human medicine European public assessment report (EPAR): Tegsedi (updated)

inotersen sodium, Amyloidosis
Date of authorisation: 06/07/2018, , , Revision: 14, Authorised, Last updated: 02/05/2023
List item

Human medicine European public assessment report (EPAR): Ocaliva (updated)

Obeticholic acid, Liver Cirrhosis, Biliary
Date of authorisation: 12/12/2016, , , , Revision: 16, Authorised, Last updated: 02/05/2023
List item

Human medicine European public assessment report (EPAR): Zynlonta (updated)

loncastuximab tesirine, Lymphoma, Large B-Cell, Diffuse; Lymphoma, B-Cell
Date of authorisation: 20/12/2022, , , Revision: 2, Authorised, Last updated: 02/05/2023
List item

Human medicine European public assessment report (EPAR): Yselty (updated)

linzagolix choline, Leiomyoma
Date of authorisation: 14/06/2022, , Revision: 3, Authorised, Last updated: 02/05/2023
List item

Human medicine European public assessment report (EPAR): Imfinzi (updated)

durvalumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 21/09/2018, , Revision: 16, Authorised, Last updated: 02/05/2023
List item

Human medicine European public assessment report (EPAR): Zejula

Niraparib (tosilate monohydrate), Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms
Date of authorisation: 16/11/2017, , , Revision: 20, Authorised, Last updated: 28/04/2023
List item

Human medicine European public assessment report (EPAR): Palynziq

Pegvaliase, Phenylketonurias
Date of authorisation: 03/05/2019, , , Revision: 7, Authorised, Last updated: 28/04/2023
List item

Human medicine European public assessment report (EPAR): Kalydeco

ivacaftor, Cystic Fibrosis
Date of authorisation: 23/07/2012, , Revision: 35, Authorised, Last updated: 28/04/2023
List item

Human medicine European public assessment report (EPAR): Beyfortus

nirsevimab,
Date of authorisation: 31/10/2022, , Revision: 2, Authorised, Last updated: 28/04/2023
List item

Human medicine European public assessment report (EPAR): Ronapreve

casirivimab, imdevimab, COVID-19 virus infection
Date of authorisation: 12/11/2021, , Revision: 4, Authorised, Last updated: 28/04/2023
List item

Human medicine European public assessment report (EPAR): NexoBrid

proteolytic enzymes enriched in bromelain, Debridement
Date of authorisation: 18/12/2012, , Revision: 15, Authorised, Last updated: 26/04/2023
List item

Human medicine European public assessment report (EPAR): Lyumjev (previously Liumjev)

insulin lispro, Diabetes Mellitus
Date of authorisation: 24/03/2020, , Revision: 5, Authorised, Last updated: 25/04/2023
List item

Human medicine European public assessment report (EPAR): Verkazia

ciclosporin, Conjunctivitis; Keratitis
Date of authorisation: 06/07/2018, , , Revision: 7, Authorised, Last updated: 25/04/2023
List item

Human medicine European public assessment report (EPAR): Translarna

Ataluren, Muscular Dystrophy, Duchenne
Date of authorisation: 31/07/2014, , , , Revision: 22, Authorised, Last updated: 25/04/2023
List item

Human medicine European public assessment report (EPAR): Sarclisa

Isatuximab, Multiple Myeloma
Date of authorisation: 30/05/2020, , Revision: 7, Authorised, Last updated: 25/04/2023
List item

Human medicine European public assessment report (EPAR): Rubraca

rucaparib camsylate, Ovarian Neoplasms
Date of authorisation: 23/05/2018, , , Revision: 12, Authorised, Last updated: 24/04/2023
List item

Human medicine European public assessment report (EPAR): Artesunate Amivas

artesunate, Malaria
Date of authorisation: 22/11/2021, , , Revision: 1, Authorised, Last updated: 24/04/2023
List item

Human medicine European public assessment report (EPAR): Rinvoq

upadacitinib, Arthritis, Rheumatoid
Date of authorisation: 16/12/2019, , , Revision: 14, Authorised, Last updated: 24/04/2023
List item

Human medicine European public assessment report (EPAR): Epclusa

Sofosbuvir, velpatasvir, Hepatitis C, Chronic
Date of authorisation: 06/07/2016, , Revision: 20, Authorised, Last updated: 21/04/2023
List item

Human medicine European public assessment report (EPAR): Uplizna

Inebilizumab, Neuromyelitis Optica
Date of authorisation: 25/04/2022, , Revision: 2, Authorised, Last updated: 21/04/2023
List item

Human medicine European public assessment report (EPAR): Regkirona

Regdanvimab, COVID-19 virus infection
Date of authorisation: 12/11/2021, , Revision: 7, Authorised, Last updated: 21/04/2023
List item

Human medicine European public assessment report (EPAR): Lunsumio

mosunetuzumab, Lymphoma, Follicular
Date of authorisation: 03/06/2022, , , , Revision: 1, Authorised, Last updated: 20/04/2023
List item

Human medicine European public assessment report (EPAR): Fintepla

Fenfluramine hydrochloride, Epilepsies, Myoclonic
Date of authorisation: 18/12/2020, , , Revision: 5, Authorised, Last updated: 20/04/2023
List item

Human medicine European public assessment report (EPAR): Wakix

pitolisant, Narcolepsy
Date of authorisation: 31/03/2016, , , Revision: 14, Authorised, Last updated: 20/04/2023

Load more

778 results

Human medicine European public assessment report (EPAR): Xenpozyme (updated)

Human medicine European public assessment report (EPAR): Tegsedi (updated)

Human medicine European public assessment report (EPAR): Ocaliva (updated)

Human medicine European public assessment report (EPAR): Zynlonta (updated)

Human medicine European public assessment report (EPAR): Yselty (updated)

Human medicine European public assessment report (EPAR): Imfinzi (updated)

Human medicine European public assessment report (EPAR): Zejula

Human medicine European public assessment report (EPAR): Palynziq

Human medicine European public assessment report (EPAR): Kalydeco

Human medicine European public assessment report (EPAR): Beyfortus

Human medicine European public assessment report (EPAR): Ronapreve

Human medicine European public assessment report (EPAR): NexoBrid

Human medicine European public assessment report (EPAR): Lyumjev (previously Liumjev)

Human medicine European public assessment report (EPAR): Verkazia

Human medicine European public assessment report (EPAR): Translarna

Human medicine European public assessment report (EPAR): Sarclisa

Human medicine European public assessment report (EPAR): Rubraca

Human medicine European public assessment report (EPAR): Artesunate Amivas

Human medicine European public assessment report (EPAR): Rinvoq

Human medicine European public assessment report (EPAR): Epclusa

Human medicine European public assessment report (EPAR): Uplizna

Human medicine European public assessment report (EPAR): Regkirona

Human medicine European public assessment report (EPAR): Lunsumio

Human medicine European public assessment report (EPAR): Fintepla

Human medicine European public assessment report (EPAR): Wakix